Phaseline

Targets › CAMK2B

CAMK2B (Calcium/calmodulin-dependent protein kinase type II subunit beta): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Cardiovascular; next expected readout Apr 2027.

Calcium/calmodulin-dependent protein kinase that functions autonomously after Ca(2+)/calmodulin-binding and autophosphorylation, and is involved in dendritic spine and synapse formation, neuronal plasticity and regulation of sarcoplasmic reticulum Ca(2+) transport in skeletal muscle. In neurons, plays an essential structural role in the reorganization of the actin cytoskeleton during plasticity by binding and…. (UniProt, Q13554)

Open in Phaseline: the race on CAMK2B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cardurion PharmaceuticalsCRD-4730
Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor
CAMK2A, CAMK2B, CAMK2D, CAMK2GPhase 2Catecholaminergic Polymorphic Ventricular Tachycardia; Heart Failure With Reduced Ejection Fraction (HFrEF)Apr 2027

Conditions

Catecholaminergic Polymorphic Ventricular Tachycardia (1) Heart Failure With Reduced Ejection Fraction (HFrEF) (1)

Modalities

small molecule (1)

Companies

Cardurion Pharmaceuticals (1)

Related targets

CAMK2A (1) CAMK2D (1) CAMK2G (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.